Stockscreener 앱 받기
0.875
9.39%
0.0751
시간 외 거래:
.87
-0.005
-0.57%
전일 마감가:
$0.7999
열려 있는:
$0.78
하루 거래량:
188.53K
Relative Volume:
0.10
시가총액:
$6.12M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.2193
EPS:
-3.99
순현금흐름:
$-12.27M
1주 성능:
+20.19%
1개월 성능:
+5.42%
6개월 성능:
-45.31%
1년 성능:
-65.28%
1일 변동 폭
$0.7595
$0.88
1주일 범위
$0.70
$0.88
52주 변동 폭
$0.548
$2.79
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.875 | 5.59M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial - MyChesCo
Aprea to Present at Oppenheimer Healthcare Conference - MyChesCo
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aprea Therapeutics (NASDAQ:APRE) Upgraded at Zacks Research - Defense World
Aprea reports second partial response in endometrial cancer trial By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aprea Therapeutics announces additional positive clinical activity for Wee1 inhibitor, APR-1051 - marketscreener.com
Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051 - TradingView
Aprea Highlights Encouraging Phase 1 Data for APR-1051 - TipRanks
Aprea reports second partial response in endometrial cancer trial - Investing.com
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - The Manila Times
Experimental cancer drug shrinks endometrial tumor by 50% in early trial - Stock Titan
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - VISTA.Today
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
IPO Launch: Is Aprea Therapeutics Inc gaining market shareWeekly Market Summary & Daily Profit Maximizing Tips - baoquankhu1.vn
Will Aprea Therapeutics Inc. stock hit new highs in YEARQuarterly Trade Summary & Weekly High Return Forecasts - mfd.ru
Is Aprea Therapeutics Inc. a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - mfd.ru
Will Aprea Therapeutics Inc. stock go up in YEARJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growthboerse.de - boerse.de
Aprea taps veteran oncologist as clinical momentum builds for lead cancer drug - MSN
Aprea Therapeutics strengthens global patent portfolio in DNA Damage Response (DDR) cancer therapeutics - marketscreener.com
Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics - TradingView
Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Programs, Securing Exclusivity Through 2045 - Quiver Quantitative
Cancer therapy company Aprea wins patents guarding new treatments into 2045 - Stock Titan
What hedge funds are buying Aprea Therapeutics Inc.Quarterly Profit Summary & Growth Focused Stock Reports - mfd.ru
Aprea Therapeutics (APRE): Analyst Maintains Rating, Lowers Pric - GuruFocus
Aprea Taps Veteran Oncologist as Clinical Momentum Builds for Lead Cancer Drug - MyChesCo
Early cancer signal emerges as Aprea drug shrinks tumors in phase 1 trial - MSN
Aprea Therapeutics appoints Eugene Kennedy as chief medical advisor By Investing.com - Investing.com Nigeria
Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com
Aprea Therapeutics Appoints Eugene Kennedy, MD, as Chief Medical Advisor - citybiz
Aprea Therapeutics appoints Eugene Kennedy as chief medical advisor - Investing.com
Aprea Therapeutics Appoints New Chief Medical Advisor - Intellectia AI
Aprea Therapeutics Appoints Dr. Eugene Kennedy as Chief Medical Advisor to Enhance Oncology Program Development - Quiver Quantitative
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - The Manila Times
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial - MyChesCo
Aprea Therapeutics (APRE) CEO buys $25,000 in shares By Investing.com - Investing.com South Africa
Aprea Therapeutics (APRE) CEO buys $25,000 in shares - Investing.com
HC Wainwright Has Bullish Forecast for APRE FY2026 Earnings - Defense World
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Is FinWise Bancorp in a bullish channelEarnings Overview Report & Daily Market Momentum Tracking - baoquankhu1.vn
Short Squeeze: How cyclical is Aprea Therapeutics Incs revenue streamJuly 2025 Rallies & Risk Controlled Stock Alerts - baoquankhu1.vn
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.68%
자본화:
|
볼륨(24시간):